Comparison of efficacy and adverse effects of CD19/20 CART versus CD19 single-target CART in R/R DLBCL: a single-center retrospective study
This study highlights the superior efficacy of dual-target CAR T-cell therapy in managing R/R DLBCL patients. The dual-target therapy significantly extended median survival compared to CD19 single-target CAR T-cell therapy. However, the enhanced therapeutic benefits were accompanied by a higher incidence of adverse effects.
Authors
- Huina Lu
- Aibin Liang (ORCID: https://orcid.org/0000-0002-8978-1987)
- Bin Xue (ORCID: https://orcid.org/0000-0003-0571-6991)
- Lili Zhou (ORCID: https://orcid.org/0000-0001-5044-6965)
- Shiguang Ye
- Ping Li (ORCID: https://orcid.org/0000-0003-1055-9505)
- Bing Li (ORCID: https://orcid.org/0000-0003-0234-044X)
- Yan Lu (ORCID: https://orcid.org/0000-0002-8370-4059)
- Xiu Luo
- Yifan Liu (ORCID: https://orcid.org/0000-0002-6406-4252)
Institutions
- Tongji University (CN)
- Tongji Hospital (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-05-06
- DOI
- https://doi.org/10.3389/fimmu.2025.1582944
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China
- Shanghai Shen Kang Hospital Development Center